Clinical evidence and treatment requirements related to heart failure in type 2 diabetes mellitus
Abstract
Heart failure (HF), which is a common and serious complication of diabetes, has received more attention in recent years. One reason for this focus on HF is that, with a large reduction in atherothrombotic events after acute myocardial infarction, HF is a relatively more frequently encountered cardiac outcome in patients with type 2 diabetes (T2DM). Another reason is the unexpected reduction in hospitalization for HF observed in cardiovascular outcome trials with sodium-glucose co-transporter-2 inhibitors (SGLT2is).[1–3] These findings led to speculation by clinicians and researchers on whether more effort should be made to differentiate patients with diabetes at a high risk of developing HF. Type 2 diabetes and the incidence of HF A cohort study with 1.9 million people showed that HF and peripheral arterial disease were the most common manifestations of cardiovascular (CV) disease initially found in patients with T2DM. HF accounted for 14.4% of events in people with T2DM.[4] Possible mechanisms for HF in patients with T2DM may include hyperglycemia, hypertension, microvascular disease as diabetic nephropathy and autonomic neuropathy, or glycosylation of myocardial proteins. In patients with T2DM, differences between relative risks of different cardiovascular diseases provide implications for risk assessment. Patients with T2DM are susceptible to atherosclerotic cardiovascular disease (ASCVD), which might be the main reason for HF. However, HF can occur in patients with T2DM…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 271,174 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.